Entero Therapeutics (ENTO) Competitors

$2.52 +0.01 (+0.40%)

As of 05/1/2026

ENTO vs. MBRX, BLRX, CTXR, TRAW, and LIAN

Should you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Moleculin Biotech (MBRX), BioLineRx (BLRX), Citius Pharmaceuticals (CTXR), Traws Pharma (TRAW), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry.

How does Entero Therapeutics compare to Moleculin Biotech?

Entero Therapeutics (NASDAQ:ENTO) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

: Moleculin Biotech's return on equity of 0.00% beat Entero Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Entero Therapeutics N/A -461.02% -14.72%
Moleculin Biotech N/A N/A -60.88%
: Entero Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500.
: 12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Entero Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A
Moleculin Biotech N/A N/A -$33.56M -$32.75 N/A
: Moleculin Biotech has a consensus target price of $22.00, indicating a potential upside of 783.53%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Entero Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Moleculin Biotech
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: In the previous week, Moleculin Biotech had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for Moleculin Biotech and 0 mentions for Entero Therapeutics. Moleculin Biotech's average media sentiment score of 0.84 beat Entero Therapeutics' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.
Company Overall Sentiment
Entero Therapeutics Neutral
Moleculin Biotech Positive

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Moleculin Biotech	N/A	N/A	-60.88%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$32.75	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Overall Sentiment
Entero Therapeutics	Neutral
Moleculin Biotech	Positive

Summary

Moleculin Biotech beats Entero Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

: 1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.67
Entero Therapeutics
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Entero Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -99.58%. BioLineRx's return on equity of -5.61% beat Entero Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
BioLineRx -99.58% -5.61% -2.81%
Entero Therapeutics N/A -461.02% -14.72%
: BioLineRx has higher revenue and earnings than Entero Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLineRx $1.18M 11.21 -$1.17M -$0.17 N/A
Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A
: BioLineRx has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
: In the previous week, BioLineRx had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for BioLineRx and 0 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.00 beat BioLineRx's score of -0.33 indicating that Entero Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
BioLineRx Neutral
Entero Therapeutics Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-99.58%	-5.61%	-2.81%
Entero Therapeutics	N/A	-461.02%	-14.72%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.21	-$1.17M	-$0.17	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

Company	Overall Sentiment
BioLineRx	Neutral
Entero Therapeutics	Neutral

Summary

BioLineRx beats Entero Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Citius Pharmaceuticals?

Entero Therapeutics (NASDAQ:ENTO) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

: 12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Citius Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 773.36%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Entero Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Citius Pharmaceuticals
1 Sell rating(s)

2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Citius Pharmaceuticals' return on equity of -49.34% beat Entero Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Entero Therapeutics N/A -461.02% -14.72%
Citius Pharmaceuticals N/A -49.34% -28.64%
: Entero Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A
Citius Pharmaceuticals N/A N/A -$37.43M -$2.45 N/A
: Entero Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
: In the previous week, Citius Pharmaceuticals had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 4 mentions for Citius Pharmaceuticals and 0 mentions for Entero Therapeutics. Citius Pharmaceuticals' average media sentiment score of 0.16 beat Entero Therapeutics' score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
Entero Therapeutics Neutral
Citius Pharmaceuticals Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Citius Pharmaceuticals	N/A	-49.34%	-28.64%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.45	N/A

Company	Overall Sentiment
Entero Therapeutics	Neutral
Citius Pharmaceuticals	Neutral

Summary

Citius Pharmaceuticals beats Entero Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to Traws Pharma?

Entero Therapeutics (NASDAQ:ENTO) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

: In the previous week, Traws Pharma had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 4 mentions for Traws Pharma and 0 mentions for Entero Therapeutics. Traws Pharma's average media sentiment score of 0.97 beat Entero Therapeutics' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media.
Company Overall Sentiment
Entero Therapeutics Neutral
Traws Pharma Positive
: Traws Pharma has a consensus target price of $8.00, indicating a potential upside of 406.33%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Entero Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Traws Pharma
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.50
: 12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 14.0% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.
: Traws Pharma's return on equity of 112.18% beat Entero Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Entero Therapeutics N/A -461.02% -14.72%
Traws Pharma N/A 112.18% 35.31%
: Traws Pharma has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A
Traws Pharma $2.79M 5.75 $9.17M $0.93 1.70

Company	Overall Sentiment
Entero Therapeutics	Neutral
Traws Pharma	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Traws Pharma	N/A	112.18%	35.31%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Traws Pharma	$2.79M	5.75	$9.17M	$0.93	1.70

Summary

Traws Pharma beats Entero Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to LianBio?

Entero Therapeutics (NASDAQ:ENTO) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

: In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.
Company Overall Sentiment
Entero Therapeutics Neutral
LianBio Neutral
: Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
LianBio
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: LianBio's return on equity of -33.17% beat Entero Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Entero Therapeutics N/A -461.02% -14.72%
LianBio N/A -33.17% -30.19%
: Entero Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A
LianBio N/A N/A -$110.29M -$0.81 N/A
: 12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Overall Sentiment
Entero Therapeutics	Neutral
LianBio	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
LianBio	N/A	-33.17%	-30.19%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A

Summary

LianBio beats Entero Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTO vs. The Competition

Export

Metric	Entero Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.00M	$3.40B	$6.25B	$11.77B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	-1.49	22.62	24.91	23.23
Price / Sales	N/A	280.78	504.56	75.49
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	-1.03	7.05	9.67	6.69
Net Income	-$18.06M	$23.62M	$3.55B	$332.64M
7 Day Performance	12.00%	3.67%	1.70%	2.01%
1 Month Performance	5.44%	7.17%	5.62%	9.19%
1 Year Performance	137.69%	67.04%	34.42%	39.59%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTO Entero Therapeutics	N/A	$2.52 +0.4%	N/A	N/A	$4.00M	N/A	N/A	9
MBRX Moleculin Biotech	2.9489 of 5 stars	$2.56 +2.0%	$22.00 +759.4%	N/A	$13.39M	N/A	N/A	20	Upcoming Earnings
BLRX BioLineRx	0.865 of 5 stars	$2.75 -10.4%	N/A	N/A	$13.36M	$1.18M	N/A	40	News Coverage High Trading Volume
CTXR Citius Pharmaceuticals	1.521 of 5 stars	$0.70 +17.0%	$6.00 +762.1%	N/A	$13.32M	N/A	N/A	20
TRAW Traws Pharma	4.0863 of 5 stars	$1.43 +10.0%	$8.00 +459.4%	N/A	$13.20M	$2.79M	1.54	17

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTO) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (ENTO) Competitors

ENTO vs. MBRX, BLRX, CTXR, TRAW, and LIAN

How does Entero Therapeutics compare to Moleculin Biotech?

Summary

How does Entero Therapeutics compare to BioLineRx?

Summary

How does Entero Therapeutics compare to Citius Pharmaceuticals?

Summary

How does Entero Therapeutics compare to Traws Pharma?

Summary

How does Entero Therapeutics compare to LianBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (ENTO) Competitors

ENTO vs. MBRX, BLRX, CTXR, TRAW, and LIAN

How does Entero Therapeutics compare to Moleculin Biotech?

Summary

How does Entero Therapeutics compare to BioLineRx?

Summary

How does Entero Therapeutics compare to Citius Pharmaceuticals?

Summary

How does Entero Therapeutics compare to Traws Pharma?

Summary

How does Entero Therapeutics compare to LianBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTO vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools